Achilles Therapeutics plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ACHL research report →
Range $2 – $2
Price Chart
About the company
Achilles Therapeutics Plc is a clinical-stage biopharmaceutical company focused on immuno-oncology. The firm specializes in creating innovative precision T-cell therapies designed to combat a range of solid tumors. Its primary therapeutic candidates, both currently undergoing Phase I/IIa clinical trials, are CHIRON, aimed at advanced non-small cell lung cancer, and THETIS, targeting metastatic or recurrent melanoma.
- CEO
- Iraj Ali
- IPO
- 2021
- Employees
- 204
- HQ
- London, GB
Get TickerSpark's AI analysis on ACHL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $60.83M
- P/E
- -0.85
- PEG
- -0.07
- P/S
- 0.00
- P/B
- 0.42
- EV/EBITDA
- 0.94
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -41.05%
- ROIC
- -50.85%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-4,731,267-28.3%
- Op Income
- $-75,255,000
- Net Income
- $-69,665,000+2.1%
- EPS
- $-1.74+4.4%
- OCF Growth
- +18.6%
- FCF Growth
- +26.1%
- 52W High
- $1.51
- 52W Low
- $0.63
- 50D MA
- $1.33
- 200D MA
- $1.03
- Beta
- 1.25
- RSI (14)
- 76
- Avg Volume
- 1.28M
No earnings-call transcripts are available for ACHL yet.
- Free Float
- 48.8%
- Shares Outstanding
- 41.10M
- Float Shares
- 20.06M
of shares held by institutions
2 13F filers
Our ACHL coverage
Recent articles, reports, and earnings notes.
No research on ACHL yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ACHL report →Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca
globenewswire.com · Dec 24
Achilles Therapeutics Receives Approval to Transfer to Nasdaq Capital Market
globenewswire.com · Nov 19
Achilles Therapeutics Reports Third Quarter 2024 Financial Results
globenewswire.com · Nov 14
Is Achilles Therapeutics (ACHL) Stock Outpacing Its Medical Peers This Year?
zacks.com · Sep 23
Achilles Therapeutics Announces Strategic Update
globenewswire.com · Sep 19
Achilles Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Updates
globenewswire.com · Aug 14
Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines
globenewswire.com · May 22
Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
globenewswire.com · May 17
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.